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Abstract
Introduction: Inflammatory bowel disease (IBD) and ankylosing spondylitis (AS) are similar chronic inflammatory
diseases whose definitive etiology is unknown. Following recent clinical and genetic evidence supporting an
intertwined pathogenic relationship, we conducted a pilot study to measure fecal calprotectin (fCAL) and
IBD-related serologies in AS patients.
Methods: Consecutive AS patients were recruited from a long-term prospectively collected longitudinal AS cohort
at Cedars-Sinai Medical Center. Controls were recruited from Cedars-Sinai Medical Center employees or spouses of
patients with AS. Sera were tested by ELISA for IBD-associated serologies (antineutrophil cytoplasmic antibodies
(ANCA), anti-Saccharomyces cerevisiae antibody IgG and IgA, anti-I2, anti-OmpC, and anti-CBir1). The Bath
Ankylosing Spondylitis Disease Activity Index, the Bath Ankylosing Spondylitis Functional Index, and the Bath
Ankylosing Spondylitis Radiology Index were completed for AS patients.
Results: A total of 81 subjects (39 AS patients and 42 controls) were included for analysis. The average age of AS
patients was 47 years and the average disease duration was 22 years. AS patients were predominantly male; 76%
were HLA-B27-positive. Median fCAL levels were 42 μg/g and 17 μg/g in the AS group and controls, respectively
(P < 0.001). When using the manufacturer’s recommended cutoff value for positivity of 50 μg/g, stool samples of
41% of AS patients and 10% of controls were positive for fCAL (P = 0.0016). With the exception of ANCA, there
were no significant differences in antibody levels between patients and controls. Median ANCA was 6.9 ELISA units
in AS patients and 4.3 ELISA units in the controls. Among AS patients stratified by fCAL level, there were statistically
significant differences between patients and controls for multiple IBD-associated antibodies.
Conclusion: Calprotectin levels were elevated in 41% of patients with AS with a cutoff value for positivity of
50 μg/g. fCAL-positive AS patients displayed higher medians of most IBD-specific antibodies when compared with
healthy controls or fCAL-negative AS patients. Further studies are needed to determine whether fCAL can be used
to identify and characterize a subgroup of AS patients whose disease might be driven by subclinical bowel
inflammation.
Introduction
Inflammatory bowel disease (IBD) and ankylosing spondy-
litis (AS) are similar chronic inflammatory diseases whose
definitive etiology is unknown. Although both appear to
be distinct and well-defined phenotypes, there is increas-
ing clinical and genetic evidence supporting an intertwined
pathogenic relationship [1]. Clinically, 5 to 10% of all
patients with AS have concurrent IBD [2]. In patients with
AS without specific gastrointestinal complaints, macro-
scopic gut inflammation resembling Crohn’s disease has
been observed in 25 to 50% of all patients by colonoscopy
[3]. Histological analyses of gut biopsies in AS patients
have observed evidence of microscopic gut inflammation
even more frequently with a prevalence of 50 to 60% [4-7].
Alternatively, sacroiliac changes similar to those seen in
AS have been noted in 10 to 20% of patients with the pri-
mary diagnosis of IBD and 7 to 12% of IBD patients carry
the concomitant diagnosis of AS [8].
The genetic susceptibility risk is high in both conditions
[9-13] and recent studies with large and well-characterized
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cohorts support an important genetic overlap between AS
and IBD. The Icelandic genealogy database has shown that
AS and IBD have a strong elevated cross-risk ratio in first-
degree and second-degree relatives [14]. HLA-B27 contri-
butes approximately one-half of the genetic risk for AS,
and the prevalence of the HLA-B27 positivity in AS
approaches 90% [15]. In studies of patients with IBD with
associated spondylitis and sacroiliitis, the prevalence of
HLA-B27 varies from 25 to 78% depending on the study
[16]. In the absence of sacroiliitis, the prevalence of HLA-
B27 in IBD is not different from that in healthy controls
(reviewed in [17]). Recently published large genome-wide
association studies have identified multiple non-major his-
tocompatibility complex susceptibility loci that provide
additional evidence for a genetic overlap between Crohn’s
disease and AS. These loci include IL23R, STAT3, IL-12B,
TNFSF15 and the intergenic region at chr1q32. The
chr1q32 is located close to the KIF21B, a gene that
encodes for kinesin motor proteins [18]. IL-23R, STAT3
and IL-12p40 all play an important role in the Th17
inflammatory pathway.
Mucosal dysregulation may be an important pathway
linking genetic susceptibility to environmental triggers in
both conditions. Patients with IBD and AS both have
increased intestinal permeability as shown by the 31Cr-ethy-
lenediamine tetraacetic acid resorption test [19]. Loss of
tolerance to normal bowel flora as evidenced by an increase
in circulating antibodies to certain bacterial antigens has
been observed in IBD, including anti-Saccharomyces cerevi-
siae mannan antibodies (ASCA) [20], anti-Escherichia coli
outer-membrane porin C (OmpC) and anti-CBir1 flagellin
AB [21]. The same IBD-associated serologic markers pre-
sent at a greater frequency and at a higher titer in AS
patients compared with healthy controls, indicating a
potential loss of tolerance to commensal bacteria similar to
that observed in IBD patients [22-25].
Calprotectin is a neutrophil-derived protein that can be
quantified in the feces and has become established as a
marker of whole gut inflammation. The increase of fecal
calprotectin (fCAL) seen in the stool of IBD patients is a
direct result of increased neutrophil migration into the gut
lumen across inflamed mucosa (as reviewed in [26]). In
subjects with IBD, levels of fCAL correlate with endo-
scopic and histological degree of bowel inflammation
[27,28]. Furthermore, fCAL has been successfully shown
to predict relapses and detect pouchitis in patients with
IBD and to consistently differentiate IBD from irritable
bowel syndrome.
Although IBD is typically diagnosed by direct observa-
tion (colonoscopy) and confirmed with biopsy and
histology, finding alternative ways to assess subclinical
inflammation in a large cohort of patients would be bene-
ficial for epidemiologic studies and continued long-term
multi-disciplinary investigations into the relationship
between these two diseases. To further address the ques-
tion of subclinical bowel inflammation in AS patients, we
measured fCAL combined with IBD-related serologies in
this pilot exploratory study.
Materials and methods
Patient selection
Consecutive AS patients were recruited from our long-term
prospectively collected longitudinal AS cohort at Cedars-
Sinai Medical Center (CSMC) [29]. All patients were 18
years of age or older, supplied written consent, and met the
modified New York criteria for AS [30] at the time of
enrollment. Healthy controls were recruited from CSMC
employees or spouses of patients with AS. Healthy controls
were 18 years of age or older, supplied written consent, and
were free from any history of rheumatic disease or IBD. AS
patients and controls with a personal or family history of
IBD were excluded from the study. AS patients undergoing
treatment with mAbs against TNFa were either not invited
to participate or were later excluded. Patients undergoing
treatment with a soluble TNFa receptor (Enbrel; Etaner-
cept; manufactured by Immunex Corporation, Thousand
Oaks, CA 91320. Marketed by Amgen Inc., Thousand
Oaks, CA 91320 and Pfizer Inc. USA) were allowed to par-
ticipate. Patients and controls using NSAIDs within 2 days
of the stool collection were excluded. The study was
approved by the CSMC Institutional Review Board.
Laboratory methods
Stool samples
All participants collected stool samples at home or pro-
vided a sample during study visits. Stool samples were
handled according to manufacturer recommendations
(Genova Diagnostics, Asheville, NC, USA) and were frozen
within 48 hours at -20°C. Samples were coded and sent to
Genova Diagnostics for analysis.
Serum samples
All serum samples were collected during the study visit at
CSMC. Sera were tested by ELISA for the IBD-related
serologies: antineutrophil cytoplasmic antibodies (ANCA),
ASCA IgG and IgA, anti-I2, anti-OmpC, and anti-CBir1.
Serologies were all estimated by ELISA at the same time
in an effort to decrease variance. The basic laboratory
methods for the determination of each serology have been
described previously [31,32]. The results of each assay are
expressed in ELISA units.
Additional measures
The Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI), the Bath Ankylosing Spondylitis Functional
Index (BASFI), and the Bath Ankylosing Spondylitis
Radiology Index (BASRI) instruments were completed
for AS patients in addition to an assessment of periph-
eral arthritis.
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Statistical methods
ASCA results were log-transformed prior to quartile dis-
tribution. The mean age and disease duration between
fCAL-positive and fCAL-negative AS patients were ana-
lyzed using Student’s t test. The exact Fisher two-sided
test was performed to compare positivity rates for fCAL-
positive versus fCAL-negative AS patients. The Mann-
Whitney U test was performed to compare the median
values for fCAL, BASDAI score, BASRI score, and quanti-
tative antibody levels between AS patients and healthy
controls.
Results
Calprotectin samples were initially collected from 47 AS
patients and 42 healthy controls. Seven AS patients were
excluded from further analysis for use of prohibited
NSAIDs within 48 hours of the stool collection, and one
AS patient was excluded for treatment with TNFa mAb
prior to the study visit, thereby yielding a total of 81 study
participants with data suitable for analysis. Demographic
data for AS patients and controls are reported in Table 1.
The average age of the AS patients was 47 years and the
average disease duration was 22 years. AS patients were
predominantly male and 76% were HLA-B27-positive.
Positivity rates and fCAL levels are reported in Table 2.
The median fCAL levels were 42 μg/g and 17 μg/g in the
AS group and controls, respectively (P = 0.0002). When
using the manufacturer’s recommended cutoff value for
positivity of 50 μg/g, stool samples of 41% of AS patients
and 10% of controls were positive for fCAL (P = 0.0016).
Calprotectin levels for AS patients and controls are dis-
played in Figure 1. In general, the fCal levels of AS patients
are higher than the fCAL levels of controls. The highest
measured level of fCAL in the control group was 104 μg/g,
while the highest observed level in the AS group was 1,085
μg/g. Demographic and clinical parameters of AS subjects
stratified by fCAL positivity are shown in Tables 3 and 4.
There were no significant differences between the fCAL-
positive and fCAL-negative AS patients with regards to
age, gender, ethnicity, disease duration and HLA-B27 posi-
tivity. There was also no significant difference in NSAID
use or Enbrel use (Table 4). Although the median BASFI
in the fCAL-positive group was 41.6, compared with 17 in
the fCAL-negative group, this association was not statisti-
cally significant. There was no significant difference for the
BASRI or the occurrence of peripheral arthritis between
these two groups of AS patients (Table 4).
With the exception of ANCA, there were no significant
differences in antibody levels between patients and con-
trols (Table 5). The median ANCA value was 6.9 ELISA
units in AS patients and 4.3 ELISA units in the controls
(P = 0.003). At the fCAL threshold of 50 μg/g, there were
statistically significant differences between AS fCAL-posi-
tive patients and controls (P < 0.05) for ANCA, ASCA
IgG, and anti-CBir1 antibodies (9.2 vs. 4.3, 11.5 vs. 6.7,
and 27.2 vs. 15.9, respectively). There was no statistically
significant difference between the AS fCAL-negative
patients compared with the healthy controls (Table 6).
When fCAL-positive AS patients were compared with
fCAL-negative AS patients at the 50 μg/g threshold, signif-
icant differences were found in IgA ASCA levels (P =
0.05), IgG ASCA levels (P = 0.003), and Cbir1 (P = 0.002;
Table 7). A trend towards significant association was seen
in ANCA levels (P = 0.06; Table 7).
Discussion
In this exploratory study, we report a higher prevalence and
increased levels of fCAL positivity as well as an association
with the IBD serological markers ANCA, ASCA, anti-
CBir1, anti-I2 and anti-OmpC antibodies in a well-charac-
terized cohort of AS patients. The fCAL-positive AS
patients in our study displayed higher medians of most
IBD-specific antibodies when compared with healthy con-
trols or fCAL-negative AS patients. Our finding of 41% of
patients with fCAL > 50 μg/g is considerably lower than the
68% of patients with fCAL > 50 mg/kg found by Klingberg
and colleagues [33]. However, the latter group contained
AS subjects taking all of the usual clinically indicated medi-
cations, including NSAIDs and anti-TNF agents. In addi-
tion, in a small study of enthesitis-related arthritis in
children - a condition felt to be a form of pediatric spondy-
loarthritis that is typically HLA B-29-positive - fCAL was
Table 1 Demographic data for ankylosing spondylitis patients and healthy controls
Ankylosing spondylitis patients (n = 39) Healthy controls (n = 42)
Age (years) 47 (20 to 85) 39 (27 to 70)
Male 82 52
HLA-B27 76 Not available





Data presented as mean (range) or percentage.
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shown to be a distinguishing feature for this form of juve-
nile idiopathic arthritis compared with other pediatric rheu-
matologic conditions and controls [34].
The relationship between AS and IBD has been under
study in recent years. Increased gut permeability and
inflammation in AS has been observed in multiple studies;
however, the range of gut prevalence varies by the type of
method used to assess inflammation. Invasive methods
such as colonoscopies and biopsies have shown macro-
scopic and microscopic gut inflammation in 25 to 60% of
AS patients while noninvasive observational studies report
clinical overt IBD in 5 to 10% of AS patients (as reviewed
in [35]). Our study is intended to evaluate a practical
approach for further studies that will bridge the gap
between invasive methodologies to determine prevalence
of gut inflammation in AS and the less sensitive methods
utilizing clinical histories and symptoms.
Although attempts have been made in the recent past to
utilize biomarkers of gut inflammation in similar investiga-
tions such as ours, many of these studies have not con-
trolled adequately for medications that can influence gut
inflammation such as TNFa inhibitors or NSAIDs. We
attempted to address this potential limitation using strict
inclusion and exclusion criteria. mAbs against TNFa
(infliximab, adalimumab and certolizumab pegol) have
proven efficacy in IBD and are US Food and Drug Admin-
istration approved to treat IBD [36-39]. Etanercept, a
TNFa receptor fusion protein, has not been shown to be
efficacious in IBD but is widely used for AS [40]. We lim-
ited our patient study population to allow etanercept only.
Further, NSAIDs have been shown to increase gut perme-
ability and inflammation in healthy users [41]. The litera-
ture is unclear regarding how long the effects on the
intestinal mucosa caused by NSAIDs will last. The manu-
facturer of the fCAL assay used in this study (Genova
Diagnostics) recommends avoiding NSAIDs within 48
hours of collection. Adhering to this recommendation, we
observed 41% of AS patients to display positive fCAL
levels (fCAL > 50 μg/g). When all AS patients that used
NSAIDS on a regular basis were excluded, the percentage
of fCAL-positive patients changed only marginally (data
not shown).
The increase of fCAL seen in the stool of IBD patients
has been shown to be a direct result of increased neutro-
phil migration into the gut lumen across inflamed mucosa
[26], and in subjects with IBD the levels of fCAL correlate
with the endoscopic and histological degree of gut inflam-
mation in adults and children [27]. A recent meta-analysis
reported a sensitivity of 0.95 and a specificity of 0.91 for
fCAL to diagnose IBD in adults. The diagnostic precision
of fCAL had a better accuracy at a cutoff level of 100 μg/g
versus 50 μg/g [42].
Interestingly, BASFI and BASDAI scores are higher for
fCAL-positive patients compared with fCAL-negative AS
patients. This finding might suggest more disease activity
and functional disability in the group of patients with
subclinical inflammation of the gut. Prior studies have
found higher BASFI scores in ASCA-positive AS patients,
confirming our findings [23]. There are two possible
explanations for this observation. First, subclinical gut
inflammation might lead to increased gut permeability
and prolonged antigen exposure, triggering more severe
Table 2 Positivity rates and level of fecal calprotectin in ankylosing spondylitis patients and healthy controls
Ankylosing spondylitis patients (n = 39) Healthy controls (n = 42) P value
Fecal calprotectin (μg/g) 42 (16 to 1,085) 17 (16 to 104) 0.0002
Fecal calprotectin positive (positive > 50 μg/g) 16 (41%) 4 (10%) 0.0016











Figure 1 Fecal calprotectin levels in healthy controls and
patients with ankylosing spondylitis. Absolute values of fecal
calprotectin (fCAL) are shown in μg/g (y axis). Each square
represents the fCAL level of an individual healthy control (HC) and
each circle represents the fCAL of an individual patient with
ankylosing spondylitis (AS). The highest measured level of fCAL in
the control group was 104 μg/dl, while the highest observed level
in the AS group was 1,085 μg/g.
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disease as evidenced by higher BASDAI scores and more
functional disability as evidenced by higher BASFI scores.
The second possibility is that patients with higher BAS-
DAI and BASFI scores have higher levels of gut inflam-
mation due to more severe disease. Our sample numbers
are too small to make any of these distinctions, however,
and further studies are needed to confirm this interesting
finding.
Analysis of serologies revealed that there were no signifi-
cant differences between controls and fCAL-negative AS
patients. However, when fCAL-positive AS patients were
compared with fCAL-negative AS patients and controls, a
significantly higher median was found for some of the
IBD-specific antibodies. Calprotectin-positive AS patients
compared with controls have significantly higher mean
values for antibodies against OmpC, CBir1, and ANCAs,
ASCA IgG and IgA. When fCAL-positive AS patients are
compared with fCAL-negative AS patients, these findings
are confirmed for antibodies against CBir1 and ASCA IgG
and IgA, but not for antibodies against ANCA, OmpC or
I2 (although trends towards significant association are seen
with ANCA and OmpC). These results suggest that the
fCAL-positive AS patient might have prolonged antigenic
exposure to gut antigens as evidenced by the development
of serologic memory. In addition, results in fCAL-positive
AS patients suggest the importance of a potential bacterial
trigger that could provide a link to new genetic discoveries.
Our most recent findings that polymorphisms of ERAP1,
which encode an endoplasmic reticulum aminopeptidase
involved in peptide trimming before HLA class I presenta-
tion, only affects AS risk in HLA-B27-positive individuals
provides strong evidence that HLA-B27 operates in AS
through a mechanism involving aberrant processing of
antigenic peptides [43].
There are important limitations to interpreting the
results from this study. First, our sample size is small and
a larger study is required to more precisely determine the
prevalence of subclinical bowel inflammation in our own
patient cohort. Our study is cross-sectional; longitudinal
studies will be needed to determine the clinical signifi-
cance of fCAL and IBD-specific serologies in AS. Second,
although our patients were not taking NSAIDs for at least
48 hours prior to the study, there could be a carryover
effect or patients may not have been compliant with the
instructions. Third, we do not have concurrent colonosco-
pies or capsule studies of our AS patients that might con-
firm whether fCAL positivity truly correlates with bowel
inflammation. However, fCAL testing has an excellent
Table 3 Demographic data for ankylosing spondylitis patients stratified by fecal calprotectin positivity
Fecal calprotectin cutoff 50 μg/g
Fecal calprotectin positive (n = 16) Fecal calprotectin negative (n = 23) P value
Mean age (years) 45 49 0.48
Male, n (%) 14 (88) 18 (78) 0.68
HLA-B27-positive, n (%) 11 (69) 18 (82) 0.71
Mean disease duration (years) 22 22 0.96
Ethnicity (%)
Caucasian 8 74 0.71
Asian 0 13 0.26
Hispanic 19 13 0.67
Table 4 Clinical data for ankylosing spondylitis patients in stratified by fecal calprotectin positivity
Fecal calprotectin cutoff 50 μg/g
Fecal calprotectin positive (n = 16) Fecal calprotectin negative (n = 23) P value
NSAID use 6 (38%) 10 (43%) 0.75
Enbrel use 9 (56%) 8 (35%) 0.20
Patients waking up at night for bowel movement 3 (19%) 3 (13%) 0.67
BASDAI score 3.0 (0.1 to 7.75) 1.8 (0.03 to 7.66) 0.16
BASRI score 6.0 (2 to 13.5) 5.0 (2 to 11) 0.64
BASFI score 41.6 (0.4 to 92.5) 17.1 (0 to 72.1) 0.09
Erythrocyte sedimentation rate 8.5 (0 to 62) 17 (2 to 64) 0.75
C-reactive protein 0.44 (0.03 to 5.7) 0.57 (0.02 to 4.84) 0.58
Patients with history of uveitis 7 (44%) 10 (43%) 1.0
Patients with history of peripheral arthritis in the knee 4 (25%) 5 (22%) 1.0
Patients with history of peripheral arthritis in the ankle 5 (31%) 4 (17%) 0.44
Data presented as median (range) or number (percentage). BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis
functional index; BASRI, Bath ankylosing spondylitis radiology index.
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specificity and sensitivity in distinguishing IBD from non-
IBD. Further studies of these relationships will serve to
place patients in a clinical context and to provide associa-
tions with clinical characteristics, disease severity, and
treatment response. Our preliminary data suggest that
fCAL-positive AS patients have more active disease, a
finding with significant clinical implications if verified in
other studies.
Conclusion
In summary, fCAL, a fecal marker for whole gut inflam-
mation, as well as serological antibodies that have been
well studied and characterized in IBD are found in a
higher percentage of AS patients followed at our institu-
tion compared with healthy controls. Further studies,
including more patients on a variety of medications, and
longitudinal observations will be needed to prospectively
determine whether fCAL can be used to identify and
characterize a subgroup of AS patients whose disease
might be driven by subclinical bowel inflammation.
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